sac-TMT in 1L Maintenance Treatment of HRD-Negative Advanced EOC

• Research type

  Research Study

• Full title

  A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOT-ov85/GOG-3102)

• IRAS ID

  1012819

• Contact name

  - -

• Contact email

  N/A

• Sponsor organisation

  Merck Sharp & Dohme LLC

• Research summary

  Researchers are looking for new ways to treat ovarian cancer (OC).

  Current treatment for OC may start with surgery followed by chemotherapy. After chemotherapy, standard care options may include:
  • Maintenance treatment, to prevent cancer growth or return. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread.
  • Observation, which is watching to see if cancer grows or worsens

  The study medicine, sacituzumab tirumotecan (sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

  About 900 people with OC will take part in this study. They will be at least 18 years old and:
  • Have OC that has spread to other parts of the body
  • Have OC that is homologous recombination deficiency (HRD)-negative, which means the cancer cells do not have certain genetic problems that prevent cells from repairing DNA damage
  • Had treatment with platinum-based chemotherapy and the cancer did not get worse after this treatment
  • Do not have certain heart or lung problems

  Researchers will assign people by equal chance to one of two study groups:
  Group A: People will receive sac-TMT with or without bevacizumab (both given into a vein as an intravenous (IV) infusion)
  Group B: People will receive standard care, which is either bevacizumab or observation

  In both groups, people will receive bevacizumab only if they were already receiving it before they joined the study.
  A person may be in this study for about 7 years, which includes follow-up time.

  During the study, people may:
  • Give urine and blood samples
  • Have tumour and imaging tests
  • Have physical and eye examinations
  • Answer questions about how they are feeling

• REC name

  North West - Greater Manchester Central Research Ethics Committee

• REC reference

  26/NW/0041

• Date of REC Opinion

  2 Apr 2026

• REC opinion

  Further Information Favourable Opinion